Vital Therapies Inc. (Nasdaq: VTL) announced disappointing results from a Phase 3 trial of VTI-208 to treat liver failure sending the stock price plummeting $14.03 to close at $3.65.
Disappointing trial results for Vital Therapies
August 24, 2015 at 18:45 PM EDT
